The FDA this week approved...

...Boehringer Ingelheim’s Ofev for the treatment of a group of progressive lung diseases with chronic fibrosing. Ofev is now the first FDA-approved therapy in this class. For the treatment of idiopathic pulmonary fibrosis, Ofev currently holds preferred status for 4% of covered lives, growing to 33% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 3/11/20